Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection

Relebactam (REL [MK-7655]) is a novel class A/C β-lactamase inhibitor intended for use with imipenem for the treatment of Gram-negative bacterial infections. REL restores imipenem activity against some resistant strains of Klebsiella and Pseudomonas. In this multicenter, double-blind, controlled tri...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Antimicrob Agents Chemother
Main Authors: Lucasti, Christopher, Vasile, Liviu, Sandesc, Dorel, Venskutonis, Donatas, McLeroth, Patrick, Lala, Mallika, Rizk, Matthew L., Brown, Michelle L., Losada, Maria C., Pedley, Alison, Kartsonis, Nicholas A., Paschke, Amanda
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology 2016
Teme:
Clinical Therapeutics
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5038313/
https://ncbi.nlm.nih.gov/pubmed/27503659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00633-16
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki